For most patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), R-CHOP immunochemotherapy leads to complete remission and 60–70% of patients remain progression-free after 5 years. Given a median age of 65, it is relevant to disentangle how DLBCL and DLBCL therapy influence health care use among the survivors. In this nationwide study, the health care use among Danish DLBCL patients diagnosed in 2007–2015, who achieved complete remission after R-CHOP(-like) therapy, was explored and compared to matched comparators from the Danish general population. The post-remission 5-year risk of hospitalization was significantly higher among DLBCL survivors (55%) compared to matched comparators (49%, P < 0.001). DLBCL survivors had on average 10.3 (9.3–11.3) inpatient bed days within 5 years of response evaluation, whereas matched comparators had 8.4 (7.9–8.8). The rate of outpatient visits was also significantly higher(excluding routine follow-up visits, incidence rate ratio, 1.3, P < 0.001), but translated into only a very small absolute difference of <1 outpatient visits within 5 years between DLBCL survivors (4.2 visits, 95% CI, 4.0–4.4) and matched comparators (3.8 visits, 95% CI, 3.7–3.9). In conclusion, DLBCL survivors have an increased incidence of hospital visits due to a wide range of conditions, but in absolute terms the excess use of health care services in DLBCL survivors was small.
对于大多数新诊断的弥漫大B细胞淋巴瘤（DLBCL）患者，R-CHOP免疫化疗可使其达到完全缓解，且60–70%的患者在5年后仍保持无进展状态。鉴于患者中位年龄为65岁，有必要厘清DLBCL及其治疗如何影响幸存者的医疗资源使用情况。这项全国性研究探讨了2007–2015年间确诊的丹麦DLBCL患者在接受R-CHOP（或类似方案）治疗后获得完全缓解者的医疗资源使用情况，并与丹麦普通人群中匹配的对照组进行比较。结果显示，DLBCL幸存者在缓解后5年内的住院风险（55%）显著高于匹配对照组（49%，P < 0.001）。DLBCL幸存者在疗效评估后5年内平均住院床位日为10.3天（9.3–11.3），而匹配对照组为8.4天（7.9–8.8）。门诊就诊率也显著更高（排除常规随访，发生率比为1.3，P < 0.001），但5年内DLBCL幸存者（4.2次，95% CI，4.0–4.4）与匹配对照组（3.8次，95% CI，3.7–3.9）之间的绝对差异很小，不足1次。总之，DLBCL幸存者因多种疾病导致就医频率增加，但就其绝对值而言，其超额使用的医疗资源规模较小。
肿瘤(癌症)患者之家